The cell-free dna (cfdna) kits market size has grown rapidly in recent years. It will grow from $1.8 billion in 2025 to $2.02 billion in 2026 at a compound annual growth rate (CAGR) of 12.4%. The growth in the historic period can be attributed to rising adoption of liquid biopsy, growth in cancer diagnostics, increasing prenatal testing, development of PCR and NGS technologies, growth in research laboratories.
The cell-free dna (cfdna) kits market size is expected to see rapid growth in the next few years. It will grow to $3.2 billion in 2030 at a compound annual growth rate (CAGR) of 12.2%. The growth in the forecast period can be attributed to technological innovations in cfDNA kits, increasing focus on non-invasive diagnostics, AI integration in analysis, expansion of molecular testing in emerging markets, increased R&D in cancer biomarkers. Major trends in the forecast period include high-sensitivity dna isolation, automation of sample preparation, integration with ngs platforms, rapid dna extraction, standardized cfdna kits.
The increasing prevalence of genetic disorders is expected to drive the growth of the cell-free DNA (cfDNA) kits market in the coming years. Genetic disorders are medical conditions caused by alterations in a person’s DNA, which can result from mutations in one or more genes, or chromosomal abnormalities. The rising occurrence of these disorders is largely due to lifestyle changes and environmental factors such as pollution and poor diet, which can either cause genetic mutations or worsen inherited conditions. Cell-free DNA (cfDNA) kits enable early, non-invasive detection of genetic abnormalities by analyzing DNA fragments present in blood or other body fluids. This technology facilitates quicker diagnoses and allows healthcare providers to make accurate treatment decisions. For example, the Centers for Disease Control and Prevention (CDC), a U.S.-based government agency, reported in November 2024 that about 1 in every 33 newborns in the U.S. is born with a birth defect, many of which are genetically related. As a result, the increasing prevalence of genetic disorders is fueling demand for cfDNA kits.
Leading companies in the cfDNA kits market are concentrating on developing innovative products that use digital polymerase chain reaction (PCR)-based absolute quantification to enhance the sensitivity and accuracy of cfDNA analysis. Digital PCR-based absolute quantification allows for the precise detection of low-frequency genetic variants with improved consistency, making it suitable for critical applications such as cancer diagnostics, prenatal testing, and monitoring transplant rejection. For example, in June 2024, Omixon, a molecular diagnostics company based in Hungary, introduced HoloGRAFT ONE, a research-use-only kit designed to monitor donor-derived cell-free DNA (dd-cfDNA) post-transplant. This kit utilizes proprietary genetic markers and digital PCR to differentiate donor DNA from the recipient’s DNA, measuring both absolute and relative amounts of dd-cfDNA through copy-number variants. The goal of this innovative test is to enable the early detection of transplant rejection, improve patient monitoring, and support personalized post-transplant care by providing clinicians with precise cfDNA data.
In November 2025, Natera Inc., a US-based genetic testing and diagnostics firm, acquired specific reproductive health assets from Invitae for an undisclosed sum. Through this acquisition, Natera intends to broaden its molecular diagnostic offerings and expand its customer reach by incorporating Invitae’s non-invasive prenatal screening and carrier screening operations, allowing greater access to personalized genetic testing and diagnostic services. Invitae Corporation is a US-based medical genetics company focused on cell-free DNA (cfDNA) testing kits for non-invasive prenatal testing and oncology purposes.
Major companies operating in the cell-free dna (cfdna) kits market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V, Natera Inc., Myriad Genetics Inc., Guardant Health Inc., Bioneer Corporation, Streck Inc., Freenome Holdings Inc., GRAIL Inc., Zymo Research Corporation, Geneseeq Technology Inc, Covaris LLC, Active Motif Inc., Norgen Biotek Corp, AMSBIO LLC, EpiGentek Group Inc., Paragon Genomics Inc., Suzhou Beaver Biomedical Engineering.
North America was the largest region in the cell-free DNA (cfDNA) kits market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell-free dna (cfdna) kits market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell-free dna (cfdna) kits market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the cfDNA kits market by raising costs for imported reagents and extraction kits, affecting hospitals, research laboratories, and diagnostic centers. Regions like north america and europe, which import most cfDNA kits, are most affected. Positive impacts include incentivizing local production of high-quality kits and encouraging innovation in rapid, standardized extraction solutions.
The cell-free dna (cfdna) kits market research report is one of a series of new reports that provides cell-free dna (cfdna) kits market statistics, including cell-free dna (cfdna) kits industry global market size, regional shares, competitors with a cell-free dna (cfdna) kits market share, detailed cell-free dna (cfdna) kits market segments, market trends and opportunities, and any further data you may need to thrive in the cell-free dna (cfdna) kits industry. This cell-free dna (cfdna) kits market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cell-free DNA (cfDNA) kits are laboratory tools designed to isolate and analyze fragmented DNA circulating in blood or other body fluids. They support non-invasive genetic testing by providing high-quality DNA for applications such as prenatal screening, cancer diagnostics, and transplant monitoring. These kits simplify sample preparation and enhance accuracy in downstream molecular analysis.
The primary product types in the cell-free DNA (cfDNA) kits market include plasma cfDNA kits, serum cfDNA kits, urine cfDNA kits, and others. Plasma cfDNA kits are designed to isolate and analyze DNA fragments circulating in plasma, the liquid component of blood. Key technologies include next-generation sequencing (NGS), polymerase chain reaction (PCR), microarray technology, and digital PCR. Major applications encompass cancer diagnostics, prenatal testing, transplant rejection monitoring, and non-invasive disease detection. Distribution channels consist of direct sales, retail pharmacies, online platforms, and distributors, while end users include hospitals, research laboratories, diagnostic laboratories, and academic institutions.
The cell-free DNA (cfDNA) kits market consists of revenues earned by entities by providing services such as purification services, bulk services, quality control (QC) services, data integration services, and custom biomarker discovery services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell-free DNA (cfDNA) kits market also includes sales of plasma separation consumables, liquid biopsy assay kits, serum preparation kits, concentration kits, and bisulfite conversion and methylation kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The cell-free dna (cfdna) kits market size is expected to see rapid growth in the next few years. It will grow to $3.2 billion in 2030 at a compound annual growth rate (CAGR) of 12.2%. The growth in the forecast period can be attributed to technological innovations in cfDNA kits, increasing focus on non-invasive diagnostics, AI integration in analysis, expansion of molecular testing in emerging markets, increased R&D in cancer biomarkers. Major trends in the forecast period include high-sensitivity dna isolation, automation of sample preparation, integration with ngs platforms, rapid dna extraction, standardized cfdna kits.
The increasing prevalence of genetic disorders is expected to drive the growth of the cell-free DNA (cfDNA) kits market in the coming years. Genetic disorders are medical conditions caused by alterations in a person’s DNA, which can result from mutations in one or more genes, or chromosomal abnormalities. The rising occurrence of these disorders is largely due to lifestyle changes and environmental factors such as pollution and poor diet, which can either cause genetic mutations or worsen inherited conditions. Cell-free DNA (cfDNA) kits enable early, non-invasive detection of genetic abnormalities by analyzing DNA fragments present in blood or other body fluids. This technology facilitates quicker diagnoses and allows healthcare providers to make accurate treatment decisions. For example, the Centers for Disease Control and Prevention (CDC), a U.S.-based government agency, reported in November 2024 that about 1 in every 33 newborns in the U.S. is born with a birth defect, many of which are genetically related. As a result, the increasing prevalence of genetic disorders is fueling demand for cfDNA kits.
Leading companies in the cfDNA kits market are concentrating on developing innovative products that use digital polymerase chain reaction (PCR)-based absolute quantification to enhance the sensitivity and accuracy of cfDNA analysis. Digital PCR-based absolute quantification allows for the precise detection of low-frequency genetic variants with improved consistency, making it suitable for critical applications such as cancer diagnostics, prenatal testing, and monitoring transplant rejection. For example, in June 2024, Omixon, a molecular diagnostics company based in Hungary, introduced HoloGRAFT ONE, a research-use-only kit designed to monitor donor-derived cell-free DNA (dd-cfDNA) post-transplant. This kit utilizes proprietary genetic markers and digital PCR to differentiate donor DNA from the recipient’s DNA, measuring both absolute and relative amounts of dd-cfDNA through copy-number variants. The goal of this innovative test is to enable the early detection of transplant rejection, improve patient monitoring, and support personalized post-transplant care by providing clinicians with precise cfDNA data.
In November 2025, Natera Inc., a US-based genetic testing and diagnostics firm, acquired specific reproductive health assets from Invitae for an undisclosed sum. Through this acquisition, Natera intends to broaden its molecular diagnostic offerings and expand its customer reach by incorporating Invitae’s non-invasive prenatal screening and carrier screening operations, allowing greater access to personalized genetic testing and diagnostic services. Invitae Corporation is a US-based medical genetics company focused on cell-free DNA (cfDNA) testing kits for non-invasive prenatal testing and oncology purposes.
Major companies operating in the cell-free dna (cfdna) kits market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V, Natera Inc., Myriad Genetics Inc., Guardant Health Inc., Bioneer Corporation, Streck Inc., Freenome Holdings Inc., GRAIL Inc., Zymo Research Corporation, Geneseeq Technology Inc, Covaris LLC, Active Motif Inc., Norgen Biotek Corp, AMSBIO LLC, EpiGentek Group Inc., Paragon Genomics Inc., Suzhou Beaver Biomedical Engineering.
North America was the largest region in the cell-free DNA (cfDNA) kits market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell-free dna (cfdna) kits market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell-free dna (cfdna) kits market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the cfDNA kits market by raising costs for imported reagents and extraction kits, affecting hospitals, research laboratories, and diagnostic centers. Regions like north america and europe, which import most cfDNA kits, are most affected. Positive impacts include incentivizing local production of high-quality kits and encouraging innovation in rapid, standardized extraction solutions.
The cell-free dna (cfdna) kits market research report is one of a series of new reports that provides cell-free dna (cfdna) kits market statistics, including cell-free dna (cfdna) kits industry global market size, regional shares, competitors with a cell-free dna (cfdna) kits market share, detailed cell-free dna (cfdna) kits market segments, market trends and opportunities, and any further data you may need to thrive in the cell-free dna (cfdna) kits industry. This cell-free dna (cfdna) kits market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cell-free DNA (cfDNA) kits are laboratory tools designed to isolate and analyze fragmented DNA circulating in blood or other body fluids. They support non-invasive genetic testing by providing high-quality DNA for applications such as prenatal screening, cancer diagnostics, and transplant monitoring. These kits simplify sample preparation and enhance accuracy in downstream molecular analysis.
The primary product types in the cell-free DNA (cfDNA) kits market include plasma cfDNA kits, serum cfDNA kits, urine cfDNA kits, and others. Plasma cfDNA kits are designed to isolate and analyze DNA fragments circulating in plasma, the liquid component of blood. Key technologies include next-generation sequencing (NGS), polymerase chain reaction (PCR), microarray technology, and digital PCR. Major applications encompass cancer diagnostics, prenatal testing, transplant rejection monitoring, and non-invasive disease detection. Distribution channels consist of direct sales, retail pharmacies, online platforms, and distributors, while end users include hospitals, research laboratories, diagnostic laboratories, and academic institutions.
The cell-free DNA (cfDNA) kits market consists of revenues earned by entities by providing services such as purification services, bulk services, quality control (QC) services, data integration services, and custom biomarker discovery services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell-free DNA (cfDNA) kits market also includes sales of plasma separation consumables, liquid biopsy assay kits, serum preparation kits, concentration kits, and bisulfite conversion and methylation kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Cell-Free DNA (cfDNA) Kits Market Characteristics
3. Cell-Free DNA (cfDNA) Kits Market Supply Chain Analysis
4. Global Cell-Free DNA (cfDNA) Kits Market Trends and Strategies
5. Cell-Free DNA (cfDNA) Kits Market Analysis of End Use Industries
7. Global Cell-Free DNA (cfDNA) Kits Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Cell-Free DNA (cfDNA) Kits Total Addressable Market (TAM) Analysis for the Market
9. Cell-Free DNA (cfDNA) Kits Market Segmentation
10. Cell-Free DNA (cfDNA) Kits Market Regional and Country Analysis
11. Asia-Pacific Cell-Free DNA (cfDNA) Kits Market
12. China Cell-Free DNA (cfDNA) Kits Market
13. India Cell-Free DNA (cfDNA) Kits Market
14. Japan Cell-Free DNA (cfDNA) Kits Market
15. Australia Cell-Free DNA (cfDNA) Kits Market
16. Indonesia Cell-Free DNA (cfDNA) Kits Market
17. South Korea Cell-Free DNA (cfDNA) Kits Market
18. Taiwan Cell-Free DNA (cfDNA) Kits Market
19. South East Asia Cell-Free DNA (cfDNA) Kits Market
20. Western Europe Cell-Free DNA (cfDNA) Kits Market
21. UK Cell-Free DNA (cfDNA) Kits Market
22. Germany Cell-Free DNA (cfDNA) Kits Market
23. France Cell-Free DNA (cfDNA) Kits Market
24. Italy Cell-Free DNA (cfDNA) Kits Market
25. Spain Cell-Free DNA (cfDNA) Kits Market
26. Eastern Europe Cell-Free DNA (cfDNA) Kits Market
27. Russia Cell-Free DNA (cfDNA) Kits Market
28. North America Cell-Free DNA (cfDNA) Kits Market
29. USA Cell-Free DNA (cfDNA) Kits Market
30. Canada Cell-Free DNA (cfDNA) Kits Market
31. South America Cell-Free DNA (cfDNA) Kits Market
32. Brazil Cell-Free DNA (cfDNA) Kits Market
33. Middle East Cell-Free DNA (cfDNA) Kits Market
34. Africa Cell-Free DNA (cfDNA) Kits Market
36. Cell-Free DNA (cfDNA) Kits Market Competitive Landscape and Company Profiles
37. Cell-Free DNA (cfDNA) Kits Market Other Major and Innovative Companies
40. Cell-Free DNA (cfDNA) Kits Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Cell-Free DNA (cfDNA) Kits Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses cell-free dna (cfdna) kits market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cell-free dna (cfdna) kits? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cell-free dna (cfdna) kits market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Plasma Cell-Free DNA (Cfdna) Kits; Serum Cell-Free DNA (Cfdna) Kits; Urine Cell-Free DNA (Cfdna) Kits; Other Product Types2) By Technology: Next-Generation Sequencing (NGS); Polymerase Chain Reaction (PCR); Microarray Technology; Digital Polymerase Chain Reaction(PCR)
3) By Application: Cancer Diagnostics; Prenatal Testing; Transplant Rejection Monitoring; Non-Invasive Disease Detection
4) By Distribution Channel: Direct Sales; Retail Pharmacies; Online Sales; Distributors
5) By End User: Hospitals; Research Laboratories; Diagnostic Laboratories; Academic Institutions
Subsegments:
1) By Plasma Cell-Free DNA Kits: Single-Stranded DNA Kits; Double-Stranded DNA Kits; High-Sensitivity DNA Kits; Rapid Extraction DNA Kits2) By Serum Cell-Free DNA Kits: Low-Volume DNA Kits; High-Yield DNA Kits; Automated DNA Kits; Manual Extraction DNA Kits
3) By Urine Cell-Free DNA Kits: Early Detection DNA Kits; Concentration DNA Kits; High-Purity DNA Kits; Long-Term Stability DNA Kits
4) By Other Product Types: Saliva DNA Kits; Cerebrospinal Fluid DNA Kits; Amniotic Fluid DNA Kits; Tissue-Derived DNA Kits
Companies Mentioned: F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific Inc.; Agilent Technologies Inc.; Illumina Inc.; Bio-Rad Laboratories Inc.; QIAGEN N.V; Natera Inc.; Myriad Genetics Inc.; Guardant Health Inc.; Bioneer Corporation; Streck Inc.; Freenome Holdings Inc.; GRAIL Inc.; Zymo Research Corporation; Geneseeq Technology Inc; Covaris LLC; Active Motif Inc.; Norgen Biotek Corp; AMSBIO LLC; EpiGentek Group Inc.; Paragon Genomics Inc.; Suzhou Beaver Biomedical Engineering.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Cell-Free DNA (cfDNA) Kits market report include:- F. Hoffmann-La Roche Ltd
- Thermo Fisher Scientific Inc.
- Agilent Technologies Inc.
- Illumina Inc.
- Bio-Rad Laboratories Inc.
- QIAGEN N.V
- Natera Inc.
- Myriad Genetics Inc.
- Guardant Health Inc.
- Bioneer Corporation
- Streck Inc.
- Freenome Holdings Inc.
- GRAIL Inc.
- Zymo Research Corporation
- Geneseeq Technology Inc
- Covaris LLC
- Active Motif Inc.
- Norgen Biotek Corp
- AMSBIO LLC
- EpiGentek Group Inc.
- Paragon Genomics Inc.
- Suzhou Beaver Biomedical Engineering.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 2.02 Billion |
| Forecasted Market Value ( USD | $ 3.2 Billion |
| Compound Annual Growth Rate | 12.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 23 |
